Imovane (Zopiclone)

Zopiclone binds to a specific site on the GABA‑A receptor complex, acting as a positive allosteric modulator. By enhancing GABA’s inhibitory action, it increases chloride influx into neurons, leading to reduced neuronal excitability and a sedative effect that facilitates sleep.

The appropriate dose of Imovane is determined by the prescribing clinician based on the patient’s age, medical condition, and response to therapy. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for Zopiclone in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Imovane product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imovane (Zopiclone) belongs to the cyclopyrrolone class, offering a rapid onset of action similar to benzodiazepine hypnotics but with a distinct chemical structure. Compared with non‑benzodiazepine agents like zolpidem, Zopiclone may have a slightly longer half‑life, which can be advantageous for maintaining sleep but may increase next‑day residual effects in some patients.

Imovane tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date indicated on the packaging.

Imovane is taken orally, usually shortly before bedtime. The tablet should be swallowed whole with a glass of water and not be taken with or immediately after a heavy meal, as food can delay absorption. Patients should ensure they have a full night’s sleep opportunity (7‑8 hours) before the next dose.

Serious risks include complex sleep behaviours such as sleep‑walking or driving while not fully awake, allergic reactions, and rare cases of respiratory depression, especially when combined with other central nervous system depressants. Patients should seek immediate medical attention if they experience unusual thoughts, hallucinations, or breathing difficulties.

Imovane is contraindicated in patients with known hypersensitivity to Zopiclone or any excipients, severe hepatic impairment, and those with a history of severe sleep‑related behaviours (e.g., sleep‑walking). Caution is also advised for individuals with uncontrolled narrow‑angle glaucoma, severe respiratory disease, or who are currently using other potent CNS depressants.